Perspective Therapeutics (CATX) Stock Analysis & Winston Score

Perspective Therapeutics is a small biotech company focused on targeted alpha therapy, a type of cancer treatment that delivers radiation directly to tumor cells while trying to spare healthy tissue. Its lead programs use a radioactive element called actinium to treat cancers such as melanoma and prostate cancer. The company sells nothing commercially yet — it is still running clinical trials to test whether its treatments are safe and effective enough to win FDA approval. The company earns almost no revenue today and funds its operations through stock offerings and partnerships, which is typical for early-stage drug developers. It operates primarily in the United States and has a market cap of roughly $200 million, reflecting the high-risk, high-uncertainty nature of its pipeline. The main growth driver is advancing its clinical trials toward regulatory approval, but the biggest risk is that those trials could fail, which would severely damage the company's prospects and require it to raise more cash to survive.